Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors

Rindi, 2008, Gastroenteropancreatic neuroendocrine tumours, Lancet Oncol, 9, 61, 10.1016/S1470-2045(07)70410-2

Evans, 2008, One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the united states, J Clin Oncol, 26, 3063, 10.1200/JCO.2007.15.4377

Oberg, 2011, Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours, Endocr Relat Cancer, 18, S17, 10.1530/ERC-10-0280

Schally, 1988, Oncological applications of somatostatin analogues, Cancer Res, 48, 6977

Hofland, 1996, Octreotide, N Engl J Med, 334, 246, 10.1056/NEJM199601253340408

Gress, 2009, Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group, J Clin Oncol, 27, 4656, 10.1200/JCO.2009.22.8510

Martinez, 2014, Lanreotide in metastatic enteropancreatic neuroendocrine tumors, N Engl J Med, 371, 224, 10.1056/NEJMoa1316158

Scoazec, 2010, VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mtor pathway, Neuroendocrinology, 91, 268, 10.1159/000289569

Rinke, 2012, Antitumor effects of somatostatin analogs in neuroendocrine tumors, Oncologist, 17, 747, 10.1634/theoncologist.2011-0458

Caplin, 2013, Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors, Semin Oncol, 40, 56, 10.1053/j.seminoncol.2012.11.006

Yalcin, 2013, A review of the use of somatostatin analogs in oncology, Onco Targets Ther, 6, 471, 10.2147/OTT.S39987

Castaño, 2009, Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors, J Clin Endocrinol Metab, 94, 2634, 10.1210/jc.2008-2564

Castaño, 2010, Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents, Cell Mol Life Sci, 67, 1147, 10.1007/s00018-009-0240-y

Zatelli, 2009, Antiproliferative effects of somatostatin analogs in endocrine tumours, F1000 Med Rep, 1

Stalla, 2013, Somatostatin receptors: From signaling to clinical practice, Front Neuroendocrinol, 34, 228, 10.1016/j.yfrne.2013.07.005

Hofland, 2002, Somatostatin analogs in the diagnosis and treatment of cancer, Trends Endocrinol Metab, 13, 451, 10.1016/S1043-2760(02)00667-7

Pyronnet, 2012, Clinical review: Current scientific rationale for the use of somatostatin analogs and mtor inhibitors in neuroendocrine tumor therapy, J Clin Endocrinol Metab, 97, 727, 10.1210/jc.2011-2088

Castaño, 2012, The new truncated somatostatin receptor variant sst5tmd4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells, Oncogene, 31, 2049, 10.1038/onc.2011.389

Castaño, 2010, A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5tmd4, in pituitary adenomas poorly responsive to somatostatin analogs, J Clin Endocrinol Metab, 95, 2497, 10.1210/jc.2009-2247

Vidal, 2014, The truncated isoform of somatostatin receptor5 (sst5tmd4) is associated with poorly differentiated thyroid cancer, PLoS One, 9, e85527, 10.1371/journal.pone.0085527

Zatelli, 2015, The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells, Endocrine, 50, 442, 10.1007/s12020-015-0594-x

Davis-Smyth, 1997, The biology of vascular endothelial growth factor, Endocr Rev, 18, 4, 10.1210/edrv.18.1.0287

Jones, 2003, Not just angiogenesis—wider roles for the angiopoietins, J Pathol, 201, 515, 10.1002/path.1452

Olsen, 2006, Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling, Exp Cell Res, 312, 630, 10.1016/j.yexcr.2005.09.002

Augustin, 2006, Angiopoietins: A link between angiogenesis and inflammation, Trends Immunol, 27, 552, 10.1016/j.it.2006.10.004

Lang, 2002, Angiopoietin-2 displays vegf-dependent modulation of capillary structure and endothelial cell survival, Proc Natl Acad Sci U S A, 99, 11205, 10.1073/pnas.172161899

Marazuela, 2010, The association of the angiopoietin/tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors, Endocr Relat Cancer, 17, 897, 10.1677/ERC-10-0020

Schettini, 1999, Somatostatin controls kaposi's sarcoma tumor growth through inhibition of angiogenesis, FASEB J, 13, 647, 10.1096/fasebj.13.6.647

Albini, 2003, Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities, Endocrinology, 144, 1574, 10.1210/en.2002-220949

Florio, 2005, Somatostatin receptor subtype-dependent regulation of nitric oxide release: Involvement of different intracellular pathways, Mol Endocrinol, 19, 255, 10.1210/me.2004-0280

Tacca, 1997, Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995), Clin Cancer Res, 3, 265

Buchan, 2000, Somatostatin receptor subtype expression and function in human vascular tissue, Am J Physiol Heart Circ Physiol, 278, H1815, 10.1152/ajpheart.2000.278.6.H1815

Thanos, 2011, VEGF, ang-2 and SRIF associated abnormal postnatal development of the retinal capillary network in the royal college of surgeons rat, Exp Eye Res, 92, 128, 10.1016/j.exer.2010.12.002

McNicol, 2006, TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system, Virchows Arch, 449, 395, 10.1007/s00428-006-0250-1

Wiedenmann, 2007, TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system, Virchows Arch, 451, 757, 10.1007/s00428-007-0452-1

Solcia, 2010, Nomenclature and classification of neuroendocrine neoplasms of the digestive system, WHO Classification of Tumours of the Digestive System, 4, 13

Halperin, 2007, Manual GETNE de Diagnóstico y tratamiento de los Tumores Neuroendocrinos, 1

Thompson, 1991, Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth, Gastroenterology, 101, 303, 10.1016/0016-5085(91)90004-5

Kono, 1990, A somatostatin-secreting cell line established from a human pancreatic islet cell carcinoma (somatostatinoma): Release experiment and immunohistochemical study, Cancer Res, 50, 3691

Gadelha, 2007, Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas, Eur J Endocrinol, 156, 65, 10.1530/eje.1.02313

Tan, 2013, Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations, Br J Cancer, 108, 429, 10.1038/bjc.2012.538

Rougier, 2001, Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours, Eur J Cancer, 37, 1014, 10.1016/S0959-8049(01)00073-9

Lupp, 2015, Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy, Oncotarget, 6, 27566, 10.18632/oncotarget.4491

Condeelis, 2005, Tumor cells caught in the act of invading: Their strategy for enhanced cell motility, Trends Cell Biol, 15, 138, 10.1016/j.tcb.2005.01.003

Grabowski, 2014, PI3K-AKT-mTOR-signaling and beyond: The complex network in gastroenteropancreatic neuroendocrine neoplasms, Theranostics, 4, 336, 10.7150/thno.7851

Bruns, 2003, Opportunities in somatostatin research: Biological, chemical and therapeutic aspects, Nat Rev Drug Discov, 2, 999, 10.1038/nrd1255

Holst, 2003, Somatostatin receptors, Biochim Biophys Acta, 1616, 1, 10.1016/S0005-2736(03)00235-9

Florio, 2008, Somatostatin/somatostatin receptor signalling: Phosphotyrosine phosphatases, Mol Cell Endocrinol, 286, 40, 10.1016/j.mce.2007.08.012

Ferrara, 2008, Role of bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression, Proc Natl Acad Sci U S A, 105, 2640, 10.1073/pnas.0712185105

Del Tacca, 2007, antiangiogenic activity of selective somatostatin subtype-1 receptor agonists, Eur J Clin Invest, 37, 700, 10.1111/j.1365-2362.2007.01848.x

Bagnoli, 2007, Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: Results from transgenic mice, Invest Ophthalmol Vis Sci, 48, 3480, 10.1167/iovs.06-1469

Held-Feindt, 2001, Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells, Int J Cancer, 92, 545, 10.1002/ijc.1223